📊 DARE Key Takeaways
Is Dare Bioscience, Inc. (DARE) a Good Investment?
Dare Bioscience is in severe financial distress with near-zero revenue (down 99.7% YoY) while burning substantial cash. The company is losing approximately $1.82 for every dollar of revenue and bleeding $11.3M annually from operations, threatening its 2.9 years of cash runway. Despite adequate current liquidity, the lack of revenue generation combined with massive operating losses indicates a pre-commercialization or failed-pipeline biotech company facing existential risk.
Dare Bioscience’s fundamentals are very weak: revenue has effectively disappeared, losses remain large, and margins are deeply negative, indicating the business is still dependent on external funding rather than self-sustaining operations. The balance sheet is supported by cash and no meaningful long-term debt, but very thin equity, ongoing cash burn, and limited revenue visibility materially weaken financial quality.
Why Buy Dare Bioscience, Inc. Stock? DARE Key Strengths
- Adequate cash position of $23.1M provides runway for operations
- Low leverage with no long-term debt and 0.0x debt-to-equity ratio
- Minimal current liabilities with 1.18x current ratio meeting basic liquidity threshold
- Cash balance of $23.08M provides near-term operating flexibility
- No meaningful long-term debt reduces balance-sheet leverage risk
- Operating cash burn is significant but still broadly covered by existing cash in the near term
DARE Stock Risks: Dare Bioscience, Inc. Investment Risks
- Revenue collapse of 99.7% YoY indicates failed product commercialization or pipeline failure
- Operating cash burn of $11.3M annually will exhaust cash reserves within 2 years
- Operating margin of -185,378% and net margin of -183,483% demonstrate unsustainable business model
- Negative FCF of -$11.5M with negative ROE of -418% indicates value destruction
- Pharmaceutical R&D company without meaningful revenue suggests products failed FDA approval or market acceptance
- Revenue fell 99.7% YoY to nearly zero, showing extremely poor revenue stability and commercialization traction
- Persistent operating and net losses with deeply negative margins indicate no path to profitability is yet visible in reported fundamentals
- Equity of only $2.86M against $27.89M of liabilities leaves limited balance-sheet cushion and raises future dilution or financing risk
Key Metrics to Watch
- Quarterly revenue growth and product pipeline advancement
- Operating cash burn rate and cash runway extension timeline
- Clinical trial results or regulatory approvals for pipeline candidates
- Quarterly operating cash flow and ending cash balance
- Revenue recovery and non-dilutive funding/collaboration income
Dare Bioscience, Inc. (DARE) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Dare Bioscience, Inc. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
DARE Profit Margin, ROE & Profitability Analysis
DARE vs Healthcare Sector: How Dare Bioscience, Inc. Compares
How Dare Bioscience, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Dare Bioscience, Inc. Stock Overvalued? DARE Valuation Analysis 2026
Based on fundamental analysis, Dare Bioscience, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Dare Bioscience, Inc. Balance Sheet: DARE Debt, Cash & Liquidity
DARE Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Dare Bioscience, Inc.'s revenue has declined by 90% over the 5-year period, indicating business contraction. The most recent EPS of $-0.48 indicates the company is currently unprofitable.
DARE Revenue Growth, EPS Growth & YoY Performance
DARE Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $2.3K | $1.5M | $0.17 |
| Q2 2025 | $4.3K | -$4.0M | $-0.45 |
| Q1 2025 | $9.3K | -$4.4M | $-0.50 |
| Q2 2024 | N/A | $6.2M | $0.72 |
| Q1 2024 | N/A | -$6.8M | $-0.07 |
| Q3 2023 | N/A | $414.0K | $-0.08 |
| Q2 2023 | N/A | $414.0K | $0.00 |
| Q3 2022 | N/A | $414.0K | $-0.08 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Dare Bioscience, Inc. Dividends, Buybacks & Capital Allocation
DARE SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Dare Bioscience, Inc. (CIK: 0001401914)
📋 Recent SEC Filings
❓ Frequently Asked Questions about DARE
What is the AI rating for DARE?
Dare Bioscience, Inc. (DARE) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 90% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are DARE's key strengths?
Claude: Adequate cash position of $23.1M provides runway for operations. Low leverage with no long-term debt and 0.0x debt-to-equity ratio. ChatGPT: Cash balance of $23.08M provides near-term operating flexibility. No meaningful long-term debt reduces balance-sheet leverage risk.
What are the risks of investing in DARE?
Claude: Revenue collapse of 99.7% YoY indicates failed product commercialization or pipeline failure. Operating cash burn of $11.3M annually will exhaust cash reserves within 2 years. ChatGPT: Revenue fell 99.7% YoY to nearly zero, showing extremely poor revenue stability and commercialization traction. Persistent operating and net losses with deeply negative margins indicate no path to profitability is yet visible in reported fundamentals.
What is DARE's revenue and growth?
Dare Bioscience, Inc. reported revenue of $6.5K.
Does DARE pay dividends?
Dare Bioscience, Inc. does not currently pay dividends.
Where can I find DARE SEC filings?
Official SEC filings for Dare Bioscience, Inc. (CIK: 0001401914) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is DARE's EPS?
Dare Bioscience, Inc. has a diluted EPS of $-1.18.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is DARE a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Dare Bioscience, Inc. has a STRONG SELL rating with 90% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is DARE stock overvalued or undervalued?
Valuation metrics for DARE: ROE of -418.4% (sector avg: 15%), net margin of -183,482.5% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy DARE stock in 2026?
Our dual AI analysis gives Dare Bioscience, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is DARE's free cash flow?
Dare Bioscience, Inc.'s operating cash flow is $-11.3M, with capital expenditures of $178.6K. FCF margin is -176,596.1%.
How does DARE compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -183,482.5% (avg: 12%), ROE -418.4% (avg: 15%), current ratio 1.18 (avg: 2).